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Richard A. LarsonAcute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, immu-
nophenotype, and clinical, cytogenetic, and molecular features. Modern treatment strategies use a risk-adap-
ted approach. The optimal postremission therapy for adults with ALL remains unclear. Treatment-related
morbidity and mortality (TRM) are greater with hematopoietic cell transplantation (HCT) than chemother-
apy although relapses are less common. Available data indicate no clear consensus as to whether there is an
advantage to allogeneic HCTover chemotherapy for adults with ALL with standard-risk features while in the
first complete remission (CR1). However, allogeneic HCT is recommended in CR1 for patients with high-risk
ALL and for those in a second CR.
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Acute lymphoblastic leukemic (ALL) has served as
the model for the cure of neoplasia by chemotherapy
for several decades, but evennow fewer thanhalf of adult
patients achieve long disease-free survival (DFS). Steady
improvements in the cure rate for adults have been
achieved throughmore accuratediagnoses, the use of in-
tensivemultiagent chemotherapy, attention to potential
sanctuary sites such as the central nervous system
(CNS), and the appropriate use of allogeneic hemato-
poietic cell transplantation (HCT). Further progress
will require large numbers of uniformly evaluated
patients to be entered onto randomized clinical trials,
testing various components of the total therapy that
have heretofore been added empirically. The ability to
detect minimal residual disease during remission may
identify patients who require alternative treatment and
at the same time spare some patients from unnecessarily
prolonged or toxic treatments. New drugs will likely be
required for a breakthrough in the cure rate.Department of Medicine and Cancer Research Center,
rsity of Chicago, Chicago, Illinois.
isclosure: See Acknowledgments on page 15.
dence and reprint requests: Richard A. Larson, MD, Sec-
f Hematology/Oncology, University of Chicago, MC-
5841 S. Maryland Avenue, Chicago IL 60637 (e-mail:
n@medicine.bsd.uchicago.edu).
/09/151S-0001$36.00/0
6/j.bbmt.2008.11.018Treatment regimens for ALL have evolved empir-
ically into complex schemes that use numerous agents
in various doses, combinations, and schedules. Few of
the individual components have been tested rigorously
in randomized trials. Thus, it is difficult to analyze
critically the absolute contribution of each drug or
dose schedule to the ultimate outcome. Numerous
nonrandomized trials have attempted to answer these
questions, but multiple alterations in study design be-
tween sequential trials have made it difficult to assess
the exact merit of each modification. In addition, ALL
is quite a heterogeneous disease, and outcomes vary by
age, immunophenotype, and clinical, cytogenetic, and
molecular features.
Recent clinical trials have used allogeneicHCT (al-
loHCT) within the context of modern risk-adapted
treatment of ALL in adults. However, the optimal
postremission therapy for adults with ALL remains un-
clear. Available data indicate no clear consensus as to
whether there is an advantage to alloHCT over the
best available chemotherapy for consolidation of adults
with ALL with standard-risk features while in the first
complete remission (CR1). However, alloHCT is rec-
ommended inCR1 for patients with high-risk ALL and
for those in a second CR where chemotherapy alone is
less likely to effect a cure.Risk Assessment
In analyses that included over 350 adults with
ALL treated on prospective trials with intensive chemo-
therapy, the Cancer and Leukemia Group B (CALGB)
identified the following clinical and biologic features11
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younger age (\60 years old), white blood cell (WBC)
count \30,000/mL, the presence of a mediastinal
mass, T cell immunophenotype (with or without mye-
loid markers), and absence of the Philadelphia (Ph)
chromosome [1]. Patients who had no adverse features
had a 91% estimated probability of survival at 3 years
(95% confidence interval [CI], 66%-98%). Patients
with 1 , 2, or 3 unfavorable features had 3-year survivals
of 64%, 49%, and 21%, respectively. None of the pa-
tients with 4 adverse risk factors survived more than 3
years. Survival was a continuous function of age. The
survival at 3 years for patients\30 years old was 66%
and for those 30 to 59 years old was 36%. Very few of
these patients underwent alloHCT in CR1. Similar
models have been described by others, but importantly,
the risk groups vary and are dependent upon particular
therapies [2]. In particular, prognostic factors are differ-
ent when analyzing outcomes after myeloablative ther-
apy and HCT. Universally, older age (.35 or .40
years old) or Ph1 ALL have been considered high-
risk features.
What can be expected with modern intensive che-
motherapy for adults with ALL? The outcomes of
1059 newly diagnosed patients enrolled on prospective
clinical trials since 1988 by the CALGB were recently
analyzed. Eligible patients were those over 15 years
old with no upper limit on age. Patients with Burkitt
leukemia were not included. The median age was 39
years (range: 16-83). In general, only patients with
Ph1 ALL underwent alloHCT in CR1. Clinical
characteristics and treatment outcomes are shown in
Table 1. Importantly, the survival of the 360 patients
\30 years old, including those with high-risk features,
was 59% at 3 years (95% CI, 53%-64%), and their
median survival was 62 months (95% CI, 44-91).
Most recently, attention has focused on adoles-
cents and young adults (ages 16-30 years old) with
ALL. Teenage patients are treated by either adult or
pediatric hematologists, and several retrospective
studies have reported that adolescents with ALL have
had better outcomes when treated on prospective pedi-
atric protocols than when enrolled on adult ALL pro-
tocols [3]. However, 16-17-year-old patients treated
on CALGB studies had outcomes identical to the 16-
17-year-olds treated on Children’s Cancer Group
studies, although CALGB patients 18-20 years old
did considerably worse [4]. Because there are noTable 1. Outcomes of 1059 Adults with ALLTreated on 6 Consecu
Age Group N
Median Age,
Years (Range)
Complete Remiss
Rate, % (95% C
<30 years 360 22 (18-29) 89 (85-92)
30-59 years 502 44 (30-59) 81 (77-84)
60+ years 197 67 (60-83) 61 (54-68)
CI indicates confidence interval.biologic disease differences between these 2 similar
age cohorts, it is reasonable to hypothesize that demo-
graphic differences and lackof adherence to similar pro-
tocols may underlie some of the observed differences in
outcome. Prospective trials are currently evaluating the
outcomes of young adults when treated by adult
hematologists using ‘‘pediatric’’ regimens [3,5]. Better
results from chemotherapy would impact considerably
on the need for alloHCT in this favorable group.
Allogeneic HCT for ALL
HCT has been utilized in the remission consolida-
tion phase of treatment with the hope that myeloabla-
tive chemotherapy and/or total body irradiation (TBI)
would more effectively eradicate subclinical disease
[6]. This has been shown to be beneficial in most,
but not all, studies in patients with high-risk disease re-
ceiving alloHCT (but not autologous HCT) in CR1
[6-12] (Tables 2-4). The enthusiasm for HCT for all
patients in CR1, however, has been tempered by
several studies that fail to demonstrate a significant
survival advantage of HCT over chemotherapy as con-
solidation, especially for those with standard-risk
features [6,13-15]. In some cases, for example T cell
ALL with TLX1 (HOX11) expression, early alloHCT
may diminish the excellent outcomes obtained with
chemotherapy alone [16].
There is clearly more treatment-related mortality
(TRM) as well as later morbidity (especially graft-
versus-host disease [GVHD], chronic cytopenias, infec-
tion, loss of fertility, cataracts, pulmonary difficulties,
and secondmalignancies) after alloHCT than after che-
motherapy alone. However, the relapse rate is clearly
reduced by allogeneic transplantation. Marks et al. [17]
evaluated pooled registry data regarding conditioning
regimens used for 502 matched-sibling allografts for
children and adults (#56 years old) with ALL in CR1
or CR2. All received a TBI-containing combination.
TRM did not differ whether cyclophosphamide (Cy)
or etoposide were included, nor were there significant
differences for relapse rate, leukemia-free survival
(LFS) or overall survival (OS) in CR1 by conditioning
regimen.
It has not been feasible to randomize patients with
an HLA-matched sibling donor to an alloHCT com-
pared to chemotherapy [18]. Thus, ‘‘genetic randomi-
zation’’ or assignment to HCT for those who have
suitable donors has typically been used to evaluatetive CALGB Clinical Trials between 1988 and 2007
ion
I)
Median Overall
Survival, Months (95% CI)
Overall Survival
at 3 Years, % (95% CI)
62 (44-91) 59 (53-64)
22 (19-27) 39 (35-44)
10 (7-12) 15 (10-20)
Table 2. Outcomes from the French Multicenter Study LALA-87 [7,8]
BMT Group Control Group
No. of Patients 10-Year OS (%) No. of Patients 10-Year OS (%) P-Value
Allogeneic BMT trial
All patients 116 46 141 31 .04
High risk 41 44 55 11 .009
Standard risk 75 49 86 43 NS
Autologous BMT Group Chemotherapy Group
No. of Patients 10-Year OS (%) No. of Patients 10-Year OS (%)
Autologous BMT versus
chemotherapy trial
All patients 95 34 96 29 NS
High risk 32 10 39 16 NS
Standard risk 63 49 57 40 NS
OS indicates overall survival.
Biol Blood Marrow Transplant 15:11-16, 2009 13Allogeneic HCT Is Not Recommended for ALL Adults with Standard-Risk ALL in CR1the benefit of allografts in CR1. An intention-to-treat
(ITT) analysis then evaluates outcomes from a ‘‘donor
to no-donor’’ comparison.
Between 1986 and 1991, the Leucemie Aigue¨ Lym-
phoblastique de l’Adulte performed a prospective, mul-
ticenter study (LALA-87) in adult ALL patients
comparing related donor alloHCT, autologous HCT,
and chemotherapy (Table 2) [7,8]. At CR1, 436 patients
and their siblings were HLA-typed and those 15-40
years old with an available donor (n 5 116) were as-
signed to an alloHCT using bone marrow stem cells
(BMT); 98 were actually transplanted. Patients \40
years old with no available related donor plus patients
40-50 years old (n5 262)were randomized to receive ei-
ther an autologous BMT (n5 95 were randomized; 63
actually received BMT) or chemotherapy (n5 96).Me-
dian time fromCR to alloBMTwas 63 days, andmedian
time from CR to autologous BMT was 116 days.
At a median follow-up of 38 months, there were no
significant differences between the autologous BMT
and chemotherapy groups in either 3-year DFS (39%
versus 32%; P 5 .8) or 3-year OS (49% versus 42%;
P 5 .9). By ITT, the alloBMT group had a 3-year
DFS of 43% and a 3-year OS of 55%.
Sebban et al. [11] later reported the results of a donor
to no-donor comparison from the LALA-87 trial: 116Table 3. Outcomes from the French Multicenter Study LALA-94 [
Risk Group
No. of
Patients Treatment TRM (%)
Median DFS
(Months)
Median
(Month
Standard risk 307 Chemotherapy 4 23.8 37
High risk 59 Chemotherapy 7 11 26
High risk 70 Autologous BMT 0 15.2 28
Ph+ ALL 75 Allogeneic BMT 22 15.5 21.5
Ph+ ALL 65 Autologous BMT 26 6.5 14.2
CNS+ 18 Allogeneic BMT 11.4 16
CNS+ 30 Autologous BMT 21.7 22.7
Analysis by Donor versus No-Donor Comparison for Ph+ ALL, CNS+, and Clinical High-Ri
Sibling donor 100 18 25.6
No sibling donor 159 7 13.8
TRM indicates treatment-related mortality; NS, not significant; ALL, acute lymp
system.patients with an HLA-matched donor (of whom 92
were actually transplanted in CR1; 59 with standard
risk and 33 with high-risk features) were compared
with a no-donor control group, consisting of 141 pa-
tients who had received either an autologous BMT or
chemotherapy only. Median ages were 26 and 24 years
old, respectively. No significant differences in DFS
(median, 24 months versus 22 months; P 5 .1) or OS
(median, 51 months versus 30 months; P 5 .08) were
observed.
Within a subset of 96 patients with high-risk ALL,
a significant benefit for alloBMT (n 5 41) was ob-
served compared to chemotherapy (n 5 55) with re-
spect to DFS (median, 21 versus 9 months; P 5 .01)
and OS (median, 30 versus 15 months; P5 .03). How-
ever, there was no difference in DFS or OS between
the alloBMT and chemotherapy groups among
standard-risk ALL patients. High-risk ALL patients
had at least 1 of the following: (1) Ph1 chromosome,
(2) null leukemia or undifferentiated leukemia, (3) pre-
cursor B cell ALL with at least 1 adverse prognostic
factor (age.35 years, WBC.30,000/mL or.4 weeks
to achieve CR1).
A subsequent trial by the same group (LALA-94)
between 1994 and 2002 compared related alloHCT,
autologous HCT and chemotherapy in 922 adults (15-9]
OS
s) 3-Year DFS (%) P 3-Year OS (%) P
3-Year Relapse
Rate (%) P
41 44 (5 yr) 49
24
NS
35 67
NS
39 44 54
34
.001
36
.009
53 .003
15 17 77
40 NS 40 NS
47 46
sk Patients
47 .007 51 34 0.001
34 Not stated 58
hoblastic leukemia; BMT, bone marrow transplant; CNS, central nervous
Table 4. Five-Year Estimates for OS, EFS, and Relapse for 919 Patients <50 Years Old with Ph-Negative ALL in CR1Who Received
Postremission Therapy on MRC-ECOG Study UKALLXII/E2993 [12]
5-Year Estimates No. of Patients OS (%) P EFS (%) P Relapse (%) P
Donor versus no-donor 388 versus 527 53 versus 45 <.05 50 versus 41 <.05 29 versus 54 <.05
High risk ALL 170 versus 230 39 versus 36 38 versus 32 36 versus 63 <.05
Standard-risk ALL 218 versus 286 63 versus 51 <.05 59 versus 48 <.05 25 versus 48 <.05
Randomized patients
(autologous HCT versus chemotherapy)
220 versus 215 37 versus 46 33 versus 42 <.05 61 versus 54 <.05
Donor versus
no-donor, with
chemotherapy only*
384 versus 418 54 versus 44 <.05 50 versus 40 <.05 29 versus 55 <.05
High-risk ALL 168 versus 190 41 versus 35 38 versus 31 36 versus 63 <.05
Standard risk ALL 216 versus 223 64 versus 51 <.05 59 versus 47 <.05 24 versus 48 <.05
ALL indicates acute lymphoblastic leukemia; HCT, hematopoietic cell transplant; OS, overall survival; EFS, event-free survival.
*Autologous HCT patients excluded.
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[9]. Standard-risk patients (n5 307) received only che-
motherapy; this group included all T-ALL patients
achievingCR after 1 course of chemotherapy, B-lineage
ALLpatientswithnoCNS involvement, plus thosewith
absence of Ph1, t(4;11), t(1;19) or other 11q23 rear-
rangements, WBC count \30,000/mL, CD101/
CD191 immunophenotype, CD201/CD191 immuno-
phenotype and the absence of myeloid markers, and
achievement of CR after 1 course of chemotherapy.
Their 5-year OS was 44%. The 82 high-risk patients
with an HLA-matched sibling donor were assigned to
a related alloHCT. Conditioning regimens used Cy 1
TBI (1000 cGy in a single fraction, or1200cGy in6 frac-
tions). A sibling donor versus no-donor comparison for
these high-risk patients demonstrated a significantly
better 3-year DFS in the donor group (47% versus
34%; P5 .007).
Horowitz et al. [13] retrospectively compared
related donor alloBMT in 251 adult ALL patients
from 98 hospitals worldwide reported to the Interna-
tional Bone Marrow Transplant Registry (IBMTR) to
484 chemotherapy-treated patients from 44 hospitals
enrolled on GermanMulticenter ALL (GMALL) stud-
ies. All patients were treated between 1980 and 1987,
were in CR1, and were 15-45 years of age. Adjustments
were made for time to transplant bias and differences in
disease characteristics. Prognostic factors for treatment
failurewere similar for bothgroups: immunophenotype,
WBCcount at diagnosis, and time to achieveCR1.Five-
year DFS was not significantly different between the 2
groups: 38% (95%CI, 33% to 43%) for the chemother-
apy group, and 44% (95% CI, 37% to 52%) for the
allogeneic BMT group. Zhang et al. [14] reported
long-term follow-up of the same patients. With 4 addi-
tional years of follow-up (median: 7.5 years), the 9-year
DFS was 32% in the chemotherapy group and 34% in
the related donor alloBMT group (P . .2). The inci-
dence of relapse was 66% in the chemotherapy group
and 30% for the HCT group (P\ .0001).
Ribera et al. [15] recently reported results from the
PETHEMA ALL-93 trial, which enrolled 222 adults
(15-50 years old) with high-risk, precursor-B ALL.High risk was defined as age 30-50 years old, WBC
count $25,000/mL, or adverse cytogenetics: Ph1,
t(4;11), other 11q23 rearrangements, or t(1;19). Post-
remission therapy used either a myeloablative allograft
(n5 84) or patients were randomized to an autologous
HCT (n 5 50) or chemotherapy (n5 48). A donor
versus no-donor comparison revealed no significant
differences in OS at 5 years (35% versus 44%; P 5
.35). These results did not differ when the Ph1 ALL
patients (37% of the total) were excluded.
Gupta et al. [19] reported on a single-center experi-
ence between 1992 and 2001 wherein all adults (16-55
years old) with ALL in CR1 were offered a matched re-
lated alloBMT if any donor were available (n5 48); 35
were HLA-identical siblings, 4 were a 1-antigen mis-
match, and 9 were unrelated donors. Otherwise, only
chemotherapy was given to 39 patients. After a median
follow-up of 52months, an ITT analysis showed no sig-
nificant differences in 3-year OS or event-free survival
(EFS) between the donor and no-donor groups. There
were still no significant differences in EFS or OS after
excluding the 17 patients with Ph1 ALL.
Data from the largest adult ALL trial to date
(MRC-ECOG UKALLXII/E2993) were recently
published [12,20]. In CR1, patients\50 years (55 years
since 2004) were assigned to alloHCT if they had
a compatible sibling donor. The others were random-
ized to consolidation/maintenance therapy for 2.5
years or to a single autologous transplant andno further
therapy. Prior to the assigned or randomized therapy,
all patients received intensification with 3 courses of
high-dose methotrexate. Over 1900 patients were en-
tered, 90% achieved a CR, and 1031 CR1 patients
without Ph1 ALL were HLA typed (Table 4).
The OS of all 1913 patients at 5 years was 39%. OS
at 5 years was 46% for those receiving chemotherapy
and 37% for those randomized to autologous HCT (P
5 .03). High-risk clinical features, defined as 1 of the
following: age .35 or a high WBC count (.30,000/
mL for B-lineage or .100,000/mL for T-ALL), were
present in 465 CR1 patients. Five hundred sixty-two
CR1 patents were considered to have standard-risk
ALL [20]. In a donor versus no-donor analysis, patients
Biol Blood Marrow Transplant 15:11-16, 2009 15Allogeneic HCT Is Not Recommended for ALL Adults with Standard-Risk ALL in CR1with a sibling donor (n 5 443) had improved OS than
those with no donor (n5 588), and a significantly lower
rate of relapse [20]. However, this advantage was con-
fined to standard-risk patients. The OS at 5 years for
the 239 standard-risk CR1 patients with a donor was
62% compared to 52% for the 323 similar patients
with no donor (P5 .02). The lack of demonstrable sur-
vival benefit in high-risk patients was due to high TRM
associated with age .35 years; the 2-year nonrelapse
mortality (NRM) for those patients with a donor was
36% (high risk) and 20% (standard risk) compared
with 14% (high risk) and 7% (standard risk) for those
without a donor. In an ITT analysis of chemotherapy
versus autologous HCT, patients receiving chemother-
apyonlyhad significantlybetterEFS.Thedifferencebe-
tween these 2 groups was not due to a higher mortality
but rather a higher relapse rate after autologous HCT.
Yanada et al. conducted a meta-analysis of pub-
lished data from 7 studies that included 1274 adults
with ALL [21]. Patients with donors had a significantly
better survival that those in the no-donor groups (haz-
ard ratio [HR], 1.29; 95% CI, 1.02-1.63; P 5 .037).
When only high-risk patients were analyzed, the sur-
vival advantage was greater (HR, 1.42; 95% CI, 1.06-
1.90; P5 .019). The statistics for standard-risk patients
were not reported but are likely to be considerably less
favorable than for the high-risk group.CONCLUSIONS
Using modern intensive chemotherapy that con-
tinues for 2.5 to 3 years of total therapy, approximately
60% of younger adults with ALL standard-risk features
are cured. Late treatment-related complications are un-
common after chemotherapy alone. Thus, the chronic
disease burdens and diminished quality of life associated
with alloHCT can be avoided. In addition, monitoring
forminimal residual diseasemay identify a selected subset
of ALL patients in CR1 likely to relapse and who would
most likely benefit from an early alloHCT [22,23].
AlloHCTcan rescue somepatients inCR2.Thus, the in-
discriminant recommendation for alloHCTfor all young
adults with standard-risk ALL in CR1 is unwarranted.ACKNOWLEDGMENTS
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